Immune therapy plus chemo for untreated brain lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been newly diagnosed with primary central nervous system lymphoma (PCNSL) and have not yet received any treatment for it.
- The lymphoma is limited to your brain or spinal cord and has not spread to other organs.
- Your kidneys, liver, and heart are working well enough (based on blood tests and heart function).
- You are willing to use effective birth control during the study and for 30 days after the last dose if you can become pregnant.
- You have not had certain previous cancer treatments like anti-PD-1/PD-L1 drugs or CAR-T therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a combination of drugs for people newly diagnosed with primary central nervous system lymphoma (a rare type of brain lymphoma). The treatment aims to shrink tumors and improve outcomes.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.